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Reply to Mackenzie
To the Editor:
MacKenzie suggests that, in my editorial “When Is a
Deletion Not a Deletion? When It Is Converted”
(Burghes 1997), I have not ascribed sufficient signifi-
cance to the role of the neuronal apoptosis inhibitory
protein (NAIP) gene in spinal muscular atrophy (SMA).
In particular, MacKenzie takes issue with the following
statement: “Further work is required to clearly define
the mechanism by which the converted alleles modify
phenotype, and it is possible that deletion of adjacent
genes, such as NAIP, could influence the exact severity
of the phenotype. However, it appears most likely that
the deletion of NAIP marks the extent of the deletion
and that different forms of SMNC modify the SMA phe-
notype” (Burghes 1997, p. 13).
It is my opinion that this is a fair reflection of our
current knowledge of the situation and that, at present,
there is not adequate evidence to implicate NAIP as a
major SMA-modifying gene. The first and foremost ar-
gument against involvement of NAIP comes from genetic
studies. MacKenzie indicates that, in some type I SMA
populations, the rate of NAIP deletion approaches 80%.
However, in most cases in which a noninbred population
has been studied, the rate of NAIP deletion in type I
SMAs is 45%–50% (Cobben et al. 1995; Hahnen et al.
1995; Roy et al. 1995; Thompson et al. 1995; Velasaco
et al. 1996; DiDonato et al 1997b). MacKenzie states
that “we feel it likely that motor neurons from SMA
individuals with deletions of both NAIP and SMNtel are
prone to apoptosis. As a result, the cells are less able to
withstand the stress of SMN depletion and die earlier
than they would otherwise, resulting in a more severe
form of SMA.” This would predict that the disease in
those patients without a deletion of the NAIP gene
would be mild, whereas the disease in those patients with
a NAIP gene deletion would be severe. Patients with
SMNT intragenic mutations that still retain the NAIP
gene would also be predicted to have a mild form of the
disease. So a critical question is, Do the type I SMA
cases without NAIP deletions show a clinical progression
different from that seen in patients with an NAIP de-
letion? There is no clear difference between these two
populations. In addition, type II/III SMA cases can have
deletions of NAIP, as can carriers with no clinical phe-
notype (Cobben et al. 1995; Hahnen et al. 1995; Roy
et al. 1995; Thompson et al. 1995; Rodrigues et al. 1996;
Campbell et al. 1997; DiDonato et al. 1997b). There-
fore, it does not always seem to be the case that motor
neurons lacking NAIP are more sensitive to the loss of
SMNT. It could be argued that the type I SMA cases
with an intact NAIP gene have another mutation, which
is not detectable by current assays—and that they there-
fore are phenotypically equivalent—whereas type II/III
SMA patients with a deletion of NAIP somehow make
the NAIP protein in the motor neurons. This indicates
two critical studies that are needed to substantiate NAIP
as a major modifier of SMA. First, there must be detec-
tion of intragenic NAIP mutations in the type I SMA
patients who have an intact NAIP gene. Second, there
must be studies at the protein level that show reduction
of the NAIP protein in motor neurons of type I SMA
patients who do not have a deletion of the NAIP gene.
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Apart from deletions of SMNT, type I SMA patients with
intragenic mutations of SMNT and no detectable alter-
ation in the NAIP gene have been identified (Burghes
1997, table 1). These patients have a clinical phenotype
indistinguishable from those type I SMA cases who have
NAIP deletions. If NAIP were a major modifier of SMA,
it would be difficult to explain type I SMA cases who
had an intact NAIP gene, since NAIP would be expected
to exert its protective effect and to modulate the
phenotype.
The identification of the NAIP gene in the SMA region
gave an appealing candidate gene, since it indicated that
apoptosis could have a key role in SMA. However, at
the current time, in my view, it is not clear what role
apoptosis plays in SMA. Does the motor-neuron cell
activate the apoptotic pathway because the cell lacks a
critical element or is SMA due to an actual defect in an
apoptotic pathway? Mice do not have two SMN genes
(SMNC and SMNT ) on a chromosome; rather, they have
one SMN gene on a chromosome (DiDonato et al.
1997a; Violet et al. 1997). Mice that lack this SMN gene
die early in embryogenesis (Schrank et al. 1997), and
the cells show definite apoptotic changes. This clearly
highlights the importance of the SMNC gene in human
SMA patients, but it does not explain why the loss of
SMNT causes SMA. Indeed, the SMN protein has re-
cently be shown to be important for snRNP biogenesis,
presumably a critical function in a cell (Liu et al. 1997).
Interestingly, snRNPs appear to be particularly enriched
in motor neurons. So is SMA caused by disruption of
snRNP formation in neurons or by disruption of apop-
totic pathways? What is the role of SMNC in motor
neurons? These questions remain to be resolved.
I should also note that phenotypic modification in
SMA is not entirely resolved by the conversion model
that I have presented elsewhere (Burghes 1997). In par-
ticular, there are rare type II/III SMA families in which
two sibs inherit the identical 5q13 haplotypes (Burghes
et al. 1994; Cobben et al. 1995; Hahnen et al. 1995;
Wang et al. 1996; DiDonato et al. 1997b); both sibs
have no detectable SMNT gene, but they show remark-
ably discordant phenotypes. This is not fully explainable
by the conversion model and could indicate that genes
outside the 5q13 region act as phenotypic modifiers. If
alteration of apoptotic death is implicated in SMA, then
genes such as bcl2 become candidates as phenotypic
modifiers. However, it is equally likely that phenotypic
modifiers of SMA effect the level of SMN expression in
motor neurons by up-regulating the SMNC gene to in-
crease the level of SMN protein. If this is the case, an
intriguing possibility is that up-regulation of the SMNC
gene serves as a therapeutic intervention in SMA. In
conclusion, one component that modifies phenotype in
SMA is the type of mutation in SMNT; but, as yet, it is
not clear what other factors can modify phenotype.
ARTHUR BURGHES
Department of Medical Biochemistry
Molecular Genetics and Neurology
Ohio State University
Columbus
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Evidence for Paleolithic and Neolithic Gene Flow in
Europe
To the Editor:
In recent Letters to the Editor, Cavalli-Sforza and Minch
(1997) and Richards et al. (1997) discuss the relative
contributions of the first Paleolithic colonizers of Eu-
rope, and of later Neolithic immigrants, to the gene pool
of current Europeans. Using the method of median net-
works (Bandelt et al. 1995), Richards et al. (1996) dem-
onstrated that most mitochondrial lineages coalesce at
ancestors who presumably lived in the Paleolithic period,
which, in Europe, means 110,000 years ago. Through
an analysis of the geographic distribution of these line-
ages, they reached the conclusion that most mitochon-
drial alleles spread in Europe prior to the Neolithic pe-
riod. Two implications of this finding were that (1)
farming was essentially a local development, the spread
of which was not accompanied by extensive gene flow,
and (2) the gradients of allele frequencies described in
many studies (starting with Menozzi et al. [1978] and
reviewed in Cavalli-Sforza et al. [1994]) were not due
to a Neolithic demic diffusion from the Near East (Am-
merman and Cavalli-Sforza 1984), as is generally be-
lieved. Richards et al. (1996) interpreted the results of
a simulation study of various population-expansion
mechanisms (Barbujani et al. 1995) as supporting a Pa-
leolithic origin of these clines.
Cavalli-Sforza and Minch (1997) argued that se-
quences of the mtDNA hypervariable region are not suit-
able for reconstructing evolutionary processes at this
scale, because the high mutation rates at some sites cause
an excess of random noise. In addition, a high female
mobility might have blurred some previously existing
geographic patterns. They suggested that a figure of
∼25% might realistically represent the contribution of
Neolithic immigrants to the gene pool of Europeans,
because, in principal-component analyses of allele fre-
quencies, a clinal component accounts for one quarter
of the genetic variance (Menozzi et al. 1978; Piazza et
al. 1995). If that were the case, there would be little
overall disagreement; given the approximate nature of
any such estimates, the figure (15%) proposed by Rich-
ards et al. (1997) may not differ significantly. We would
like to suggest a third possibility—namely, that the avail-
able mitochondrial data do not contradict a much larger
Neolithic contribution and that envisaging the current
European gene pool as essentially a product of an Upper
Paleolithic colonization may create more problems than
it solves.
There are four traditional reasons to believe that there
was a major Neolithic contribution to the European gene
pool: (1) the continentwide gradients of allele frequen-
cies; (2) their correlation with the archaeological record;
(3) their overlapping with areas defined by linguistic cri-
teria; and (4) their similarity to the gradients theoreti-
cally predicted under, or generated in simulation studies
of, a model of demic diffusion. None of these pieces of
evidence is proof, but in this field there is little that one
can really prove. The point, at this stage, is to find the
simplest explanation that accounts for most (or, possibly,
for all) observed population characteristics. Of course,
speaking of Paleolithic versus Neolithic processes is an
oversimplification of phenomena that were certainly
more complicated. However, such a highly schematic
opposition is useful for the sake of clarity.
As for the gradients detected for roughly one third of
the alleles studied in Europe (Sokal et al. 1989) (point
1), few doubt that they result from some form of pop-
ulation movement. Indeed, random genetic drift alone
cannot generate nonrandom patterns on such a broad
scale, and major selective effects on many independent
loci appear unlikely (Ammerman and Cavalli-Sforza
1984; but see also Fix 1996). The problem is when those
movements took place. As Richards et al. (1996, 1997)
pointed out, the correlation with archaeological gradi-
ents (point 2) and, specifically, with the first evidence of
farming activities (Sokal et al. 1991) now seems less
cogent. Indeed, evidence is emerging that, not only in
the Neolithic but also in the Paleolithic period, the main
population movements occurred along a southeast-
northwest axis (Richards et al. [1997] and references
therein). If so, whatever the relative importance of the
two temporal phases, both should have determined sim-
ilar clines of gene frequencies. On the contrary, however,
if it were shown that Paleolithic populations moved
